The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksUpdated×3•Originally published 16 April 2026•Updated 17 April 2026•

1 min read

Albertsons Beats Q4 Earnings Estimates Despite Pharmacy Sector Headwinds

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1Albertsons delivered a Q4 earnings per share (EPS) beat, surpassing analyst expectations.

2Identical sales faced headwinds driven by the Inflation Reduction Act (IRA) impacting the pharmacy segment.

about 2 months ago

Version History

Version 3about 2 months ago

What changed: Updated the story to include the company's operational scale (store count) and significant risks regarding opioid litigation and the failed merger.

Version 2about 2 months ago

What changed: The story was updated to include FY26 financial guidance, plans for increased CAPEX on automation, and analyst commentary regarding the stock's attractive intrinsic valuation.

Version 1about 2 months ago

What changed: Updated to include the 13% dividend hike, $2 billion buyback program, 21% digital sales growth, the revenue miss, and the financial impact of the opioid settlement.

Albertsons Companies, Inc. (ACI), which operates 2,244 supermarkets under banners such as Safeway and Vons, reported fourth-quarter earnings that beat estimates behind a 21% surge in digital sales. The company issued fiscal 2026 Adjusted EBITDA guidance of $3.85 billion to $3.925 billion, supported by increased CAPEX for supply chain automation. While shareholder returns were bolstered by a 13% dividend hike and a $2 billion buyback reset, the firm faces significant headwinds from a failed merger attempt. Additionally, financial liabilities related to ongoing opioid litigation remain a key concern for investors. Despite these legal and structural challenges, analysts maintain that the stock's intrinsic value exceeds current market levels.